① The cost of a monthly dose of Novartis is between 0.89 and 4.73 US dollars, which is even lower than the cost of most insulin; ② According to an analysis by 46Brooklyn Research, a non-profit drug pricing analysis agency, since many people in the US use Novartis to lose weight, the local monthly dosage is close to 970 US dollars.
Financial Services Association, March 28 (Editor: Zhao Hao) A study published in JAMA's journal “JAMA Network Open” on Wednesday (March 27) showed that$Novo-Nordisk A/S (NVO.US)$The production cost of the diabetes drug “Ozempic” (Ozempic) may be less than $5 per month.
Staff from Yale University, King's College Hospital, and Médecins Sans Frontières all participated in the study. The results report showed that the cost price (COST-based price) of a monthly dose of Novartis was between 0.89 and 4.73 dollars, which is even lower than the cost of most insulin.
The report also shows that Novotai's lowest selling price in various regions is between 38.21 and 353.74 US dollars. Also, according to an analysis by 46Brooklyn Research, a non-profit drug pricing analysis agency, since many people in the US use Novartis to lose weight, the local monthly dosage costs are close to 970 US dollars.
The study criticized the price of three diabetes treatments: insulin, SGLT-2 inhibitors, and GLP-1 drugs. One of the authors, Yale University researcher Melissa Barber, said, “There is a huge profit margin for drugs such as Novartis, and we should discuss a reasonable price level in terms of policy.”
Novo Nordisk has not disclosed the production costs of Novartis and its sister product “Vigway” Wegovy. The Danish pharmaceutical company says a large portion of its revenue is used for rebates and discounts to ensure patients receive drugs such as simeglutide.
Last year, the US government pressured pharmaceutical companies such as Novartis and Nord to cut the price of insulin by 75%. Media analysis estimates that price reduction measures have instead enabled pharmaceutical companies to obtain a larger percentage of profits because pharmaceutical companies have cancelled rebates paid to PBM (Pharmaceutical Benefits Management).
PBM has many powers, such as reviewing doctors' prescriptions, formulating prescription sets, and negotiating drug prices. Naturally, it has become a target of appeal to pharmaceutical companies. Pharmaceutical companies will give PBM and insurance companies some benefits, direct discounts or rebates in exchange for drug quotas in the prescription collection.
Also, drug developers usually use high research costs that last for several years as a reason for high pricing. Novo Nordisk said that the company spent nearly 5 billion US dollars on drug development last year and will continue to increase investment this year.
Editor/Somer